Lantern Pharma Engages IBN for Corporate Communications Strategy Amid AI-Driven Oncology Pipeline Advancements
Lantern Pharma partners with IBN to enhance investor awareness as it progresses its AI-driven oncology pipeline, including therapies for lung, brain, breast, and blood cancers.
Lantern Pharma (NASDAQ: LTRN), a biotechnology firm utilizing its RADR(R) AI platform for precision oncology drug development, has announced a partnership with IBN to spearhead its corporate communications strategy. This collaboration comes as Lantern Pharma advances its clinical programs targeting various cancers, including three AI-guided candidates and therapies under a CNS-focused subsidiary, all in active trials with FDA designations. The engagement with IBN is aimed at broadening investor awareness during a pivotal phase of pipeline development.
The company's RADR(R) platform, which integrates over 200 billion oncology-focused data points and more than 200 advanced machine learning algorithms, has significantly reduced the time and cost associated with bringing new drug programs to clinical trials. Lantern Pharma's innovative approach has enabled the advancement of drug programs from initial AI insights to first-in-human clinical trials in just 2-3 years, at an approximate cost of $2.5 million per program. This efficiency underscores the potential of AI in transforming oncology drug development, making Lantern Pharma's progress a noteworthy development in the biotech sector.
For further details on Lantern Pharma's initiatives and the full press release, visit https://ibn.fm/6gYcX. Additional news and updates regarding Lantern Pharma can be found in the company's newsroom at https://ibn.fm/LTRN.